A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
- DOI
- 10.1002/cncr.35634
- Published
- 2025 Jan 1
- Container
- Cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cncr.35634,
title = {A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.},
author = {Desai J and Wagner AJ and Carrasco Garcia I and Cesari M and Gordon M and Lin CC and Papai Z and Ryan CW and Tap WD and Trent JC and Gelderblom H and Grimison P and López Pousa A and Van Tine BA and Rubinacci M and Dai D and Rajper AW and Tecson K and Wooddell M and Stacchiotti S},
year = {2025},
journal = {Cancer},
doi = {10.1002/cncr.35634},
url = {https://doi.org/10.1002/cncr.35634}
}RIS
TY - JOUR TI - A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib. AU - Desai J AU - Wagner AJ AU - Carrasco Garcia I AU - Cesari M AU - Gordon M AU - Lin CC AU - Papai Z AU - Ryan CW AU - Tap WD AU - Trent JC AU - Gelderblom H AU - Grimison P AU - López Pousa A AU - Van Tine BA AU - Rubinacci M AU - Dai D AU - Rajper AW AU - Tecson K AU - Wooddell M AU - Stacchiotti S PY - 2025 JO - Cancer DO - 10.1002/cncr.35634 UR - https://doi.org/10.1002/cncr.35634 ER -
APA
J, D., AJ, W., I, C. G., M, C., M, G., CC, L., Z, P., CW, R., WD, T., JC, T., H, G., P, G., A, L. P., BA, V. T., M, R., D, D., AW, R., K, T., M, W., & S, S. (2025). A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.. Cancer. https://doi.org/10.1002/cncr.35634
Source records
- pubmed · retrieved 2026-09-25T07:59:44.429Z